Feldman DR, Ged Y, Lee CH, et al. - Given that encouraging activity of everolimus plus bevacizumab was seen in patients with papillary renal cell carcinoma (pRCC) and unclassified RCC (uRCC) with a major papillary component in a phase 2 study with various nonclear cell RCC (nccRCC) histologies, researchers analyzed an expanded cohort including additional patients with pRCC variants. There were 37 total evaluable patients, and among these, the 6‐month progression‐free survival (PFS) rate was estimated to be 78%, and the median PFS and objective response rate were estimated to be 13.7 months and 35%, respectively. A median overall survival of 33.9 months was seen after a median follow‐up of 17.6 months. Patients with a broad spectrum of genomic changes, including ARID1A, FH, and MET mutations, exhibited responses as shown by next‐generation sequencing results (n = 33). Overall, everolimus plus bevacizumab was confirmed to have a robust activity in metastatic pRCC variants, as per the findings of the expansion cohort. Therefore, this regimen was supported as a standard choice for this patient population.